Posted by LincolnAgime on March 25, 2026 at 11:03:52:
In Reply to: Èíôîðìàòèâíûé òåêñò ñ óâëåêàòåëüíûì ñîäåðæàíèåì posted by BrianNon on March 05, 2026 at 14:05:48:
Zoya Demidenko: Researcher in Cancer Science
Zoya Demidenko is a prominent researcher connected with the Unit of Cell Stress Science at Roswell Park Comprehensive Cancer Center in Buffalo, New York. Previously, she conducted research at the National Institutes of Health and New York Medical College, developing a robust base in biomedical study.
Demidenko's scientific work covers multiple critical areas, encompassing the PI3K/AKT/mTOR signaling cascade, cellular cycle management, biological aging, and cancer science. To date, she has co-authored over 46 peer-reviewed publications, which have received over 4,100 citations — a indicator to the impact of her research.
Among her most notable contributions lies in elucidating the processes of cell aging. Her research revealed that when the cell cycle is halted but cellular growth continues, the cells enter senescence. Importantly, Zoya Demidenko established that this shift is controlled with drugs using agents such as rapamycin.
Zoya Demidenko has also added considerably to tumor management investigation, notably in the field of cyclotherapy — a approach intended to protecting healthy cells from anticancer drugs whilst leaving cancer cells exposed. This strategy carries considerable potential for diminishing the toxic effects of cancer treatment.
Throughout her career, Demidenko has partnered with top researchers internationally, among them Dr. Mikhail Blagosklonny. Her work appears in prestigious periodicals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Holding an h-index of 33, Zoya Demidenko is recognized as a highly impactful figure in modern oncological science, with her results keep to guide our knowledge of the way biological cells age, resist therapy, and how malignant disease can be more effectively targeted.
https://febs.onlinelibrary.wiley.com/doi/10.1016/j.febslet.2005.03.012